Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Asset Writedowns and Impairment (2016 - 2018)

Historic Asset Writedowns and Impairment for Ironwood Pharmaceuticals (IRWD) over the last 3 years, with Q4 2018 value amounting to $6000.0.

  • Ironwood Pharmaceuticals' Asset Writedowns and Impairment changed N/A to $6000.0 in Q4 2018 from the same period last year, while for Sep 2019 it was $151.8 million, marking a year-over-year decrease of 116.8%. This contributed to the annual value of $151.8 million for FY2018, which is N/A changed from last year.
  • As of Q4 2018, Ironwood Pharmaceuticals' Asset Writedowns and Impairment stood at $6000.0.
  • Ironwood Pharmaceuticals' 5-year Asset Writedowns and Impairment high stood at $151.8 million for Q3 2018, and its period low was $6000.0 during Q4 2018.
  • Its 3-year average for Asset Writedowns and Impairment is $29.0 million, with a median of $5.4 million in 2014.